Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Boston Scientific Lays Out Near-Term Growth Plan

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific’s ongoing effort to reorganize and recharge its product pipeline and reduce manufacturing costs will restore higher revenue growth over the next few years, executives said during a Nov. 19 day-long investor presentation.

You may also be interested in...



Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q1 2011

For the first three months of 2011, medical device companies raised $733 million, with venture rounds bringing in $494 million. Two-thirds of the $3.9 billion in M&A activity came from Terumo's monstrous $2.6 billion cash takeover of US blood processing equipment maker CaridianBCT Holding. Buoyed by Opko Health's $105 million follow-on, the FOPO category represented almost half of the first quarter's in vitro diagnostics/research $370 million total. The stand-out IVD acquisition was Danaher's $6.8 billion takeover of publicly traded Beckman Coulter.

New Products In Brief

Boston Scientific’s next-gen defibrillators

New Products In Brief

Boston Scientific’s next-gen defibrillators

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel